This letter describes the case of an adolescent boy with heterozygous STAT1 gain-of-function syndrome and type 1 diabetes. Diabetes and other features of the syndrome resolved with the use of the Janus kinase inhibitor ruxolitinib. The patient was able to discontinue insulin therapy and remained euglycemic.
Herbert Needleman, MD, a physician-scientist whose lead in consumer products was removed due to research…
ਸਤਾਰਾਂ ਐਨਆਈਈਐਚਐਸ ਫੈਲੋਜ਼ ਨੂੰ 199 ਨੈਸ਼ਨਲ ਇੰਸਟੀਚਿ ofਟ ਆਫ਼ ਹੈਲਥ (ਐਨਆਈਐਚ) ਦੇ ਖੋਜਕਰਤਾਵਾਂ ਵਿੱਚ ਖੋਜ…
In this inaugural director’s column, I would like to share with you what makes me…
Shortly after birth, fetal hemoglobin is replaced by adult hemoglobin in red cells, a process…
As a tool of great promise for the treatment of inherited human diseases, the clustered…